论文部分内容阅读
目的探讨乙肝表面抗原阳性的B细胞性非霍奇金淋巴瘤的治疗方法及临床治疗体会。方法对我院8例乙肝表面抗原阳性的B细胞性非霍奇金淋巴瘤患者,进行R-CHOP治疗方案治疗,并对其疗效及临床不良反应进行分析总结。结果完全缓解3例占37.5%、部分缓解3例占37.5%、稳定1例占12.5%、进展1例占12.5%。所有患者使用R-CHOP方案治疗期间,均未发生寒战、心悸、胸闷、支气管痉挛、低血压等反应。5例患者治疗后出现不同程度的中性粒细胞减少、发热、贫血、恶心、呕吐、脱发等不良反应,经予以治疗后均好转,不影响治疗。结论非霍奇金淋巴瘤患者的感染HBV的患者,运用R-CHOP治疗方案治疗,能提高疗效,且不增加药物不良反应,患者耐受性好,值得临床应用。
Objective To investigate the treatment of hepatitis B surface antigen-positive B-cell non-Hodgkin’s lymphoma and its clinical experience. Methods Eight patients with B-cell non-Hodgkin’s lymphoma who were positive for hepatitis B surface antigen in our hospital were treated with R-CHOP. The curative effect and clinical adverse reactions were analyzed and summarized. The results of complete remission in 3 cases accounted for 37.5%, partial remission in 3 cases accounted for 37.5%, stable in 1 case accounted for 12.5%, progress in 1 case accounted for 12.5%. All patients using R-CHOP regimen during treatment did not occur chills, palpitations, chest tightness, bronchospasm, hypotension and other reactions. After treatment, 5 patients showed different degrees of neutropenia, fever, anemia, nausea, vomiting, hair loss and other adverse reactions, after treatment were improved, does not affect the treatment. Conclusion In patients with non-Hodgkin’s lymphoma who are infected with HBV, the treatment with R-CHOP can improve the curative effect without increasing the side effects of the drug. The patients are well tolerated and worthy of clinical application.